|
End-of-day quote
Shenzhen S.E.
2026-09-30
|
5-day change | 1st Jan Change | ||
| 4.690 CNY | +1.30% |
|
+5.63% | +7.82% |
| 09-17 | Guizhou Bailing Unit Gets China Regulator's Nod to Trial Tangning Tongluo Cream | MT |
| 09-01 | Guizhou Bailing Group Pharmaceutical Gets China Clinical Trial Approval for COPD Drug | MT |
Company Valuation: Guizhou Bailing Group Pharmaceutical Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 11,050 | 10,622 | 11,404 | 11,236 | 5,255 | 5,938 |
| Change | - | -3.87% | 7.37% | -1.47% | -53.23% | 12.99% |
| Enterprise Value (EV) 1 | 12,306 | 11,871 | 12,339 | 12,505 | 6,656 | 6,812 |
| Change | - | -3.53% | 3.94% | 1.34% | -46.78% | 2.36% |
| P/E | 71.2x | 84.4x | 81.6x | -27x | 193x | -54.4x |
| PBR | 2.84x | 2.69x | 2.85x | 3.2x | 1.65x | 1.88x |
| PEG | - | -4.6x | 7.3x | 0x | -2x | 0x |
| Capitalization / Revenue | 3.58x | 3.41x | 3.22x | 2.64x | 1.37x | 1.95x |
| EV / Revenue | 3.99x | 3.82x | 3.49x | 2.93x | 1.74x | 2.23x |
| EV / EBITDA | 42.1x | 36.6x | 40.4x | -41.9x | 53.6x | 30.7x |
| EV / EBIT | 62.6x | 51.7x | 60.8x | -31.1x | 339x | 63.1x |
| EV / FCF | 45x | 76.4x | 27.3x | 101x | 62.4x | 12.1x |
| FCF Yield | 2.22% | 1.31% | 3.66% | 0.99% | 1.6% | 8.26% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | 0.11 | 0.09 | 0.1 | -0.3 | 0.02 | -0.08 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 3,088 | 3,112 | 3,540 | 4,263 | 3,825 | 3,049 |
| EBITDA 1 | 292.4 | 324.2 | 305.6 | -298.6 | 124.1 | 221.9 |
| EBIT 1 | 196.5 | 229.5 | 203 | -402.3 | 19.62 | 108 |
| Net income 1 | 152.4 | 124.2 | 138.2 | -414.5 | 33.62 | -104.4 |
| Net Debt 1 | 1,256 | 1,249 | 935 | 1,268 | 1,400 | 874.7 |
| Reference price 2 | 7.830 | 7.600 | 8.160 | 8.110 | 3.850 | 4.350 |
| Nbr of stocks (in thousands) | 1,411,200 | 1,397,598 | 1,397,598 | 1,385,502 | 1,365,010 | 1,365,010 |
| Announcement Date | 4/29/21 | 4/22/22 | 4/28/23 | 4/29/24 | 4/28/25 | 4/27/26 |
1CNY in Million2CNY
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 954M | |
| 32.9x | 11.93x | 24.23x | 0.6% | 1,031B | |
| 29.45x | 6.54x | 18.31x | 2.02% | 638B | |
| 33.1x | 7.75x | 16.02x | 2.65% | 462B | |
| 105.72x | 5.91x | 25.05x | 2.35% | 359B | |
| 19x | 4.63x | 11.48x | 2.87% | 335B | |
| 20.37x | 5.28x | 13.08x | 3.03% | 273B | |
| 20.79x | 4.31x | 12.28x | 2.05% | 253B | |
| 26.62x | 6.92x | 12.32x | 2.39% | 228B | |
| -45.08x | 6.57x | 25.65x | 2.21% | 185B | |
| Average | 26.98x | 6.65x | 17.60x | 2.24% | 376.48B | |
| Weighted average by Cap. | 32.10x | 7.72x | 18.90x | 1.92% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- 002424 Stock
- Valuation Guizhou Bailing Group Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
